A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease

Status: Closed to Accrual

Learn more:

• https://clinicaltrials.gov/study/NCT03095352

Study Contact: studies@hoosiercancer.org; (317) 921-2050.